BNP Paribas Reiterates Neutral Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reiterated by equities research analysts at BNP Paribas in a research note issued on Monday. They presently have a GBX 5,100 ($63.72) price target on the biopharmaceutical company’s stock. BNP Paribas’ price target would indicate a potential upside of 16.93% from the company’s previous close.
A number of other equities analysts also recently issued reports on AZN. Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Tuesday, July 19th. Goldman Sachs Group Inc. reiterated a “sell” rating on shares of AstraZeneca plc in a research note on Tuesday, July 19th. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, July 20th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 4,800 ($59.97) price target on shares of AstraZeneca plc in a research note on Thursday, July 21st. Finally, Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Wednesday, July 27th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 4,947.72 ($61.82).
AstraZeneca plc (LON:AZN) opened at 4361.50 on Monday. The firm’s market cap is GBX 55.17 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The stock has a 50 day moving average price of GBX 4,794.36 and a 200 day moving average price of GBX 4,568.15.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.